The latest market report published by Credence Research, Inc., the global market for joint pain injections was valued at US$ 2,146.0 million in 2017 and is expected to reach US$ 4,888.5 million by 2026, increasing to CAGR by 9.7% from 2018 to 2026.
According to the World Health Organization (WHO) research findings, approximately 150 diseases and syndromes are classified as musculoskeletal disorders. It has a huge negative impact on the socio-economic aspects of patients. Bioventus received approval for its product Durolane in 2017 for the treatment of knee osteoarthritis, similarly Flexion Therapeutics, Inc. received FDA approval in 2017 for its product Zilretta to overcome pain associated with osteoarthritis.
Browse the full report at “Joint Pain Injections Market”
Hyaluronic acid injections are part of the injections market for joint pain injections. Its inherent properties such as excellent lubrication and shock absorbing properties significantly reduce joint stiffness and tenderness in osteoarthritis patients. Corticosteroid injections due to its anti-inflammatory properties are used as adjuvant medications to provide short-term relief for athletes with joint sprains.
Knee and ankle joints dominate the market for joint pain injections. Significant increase in tenosynovitis and prolonged physical activity are driving market growth for ankle and knee joints. The rapid growth of the production industry and the increasing competition between athletes together strengthen the growth of the market. The increased use of electronic gadgets such as mobile phones, laptops and personal computers will bring huge revenue to the shoulder and elbow joints in the coming years. Rising prevalence of rotator cuff injury further consolidates the market growth of the shoulder and elbow joints.
North America, with a share of 34 per cent, is leading the regional market for joint pain injections. The main parameters responsible for its excellent market growth are the increasing prevalence of obesity and the high acceptance of viscosupplementation in the treatment of joint pain. The existence of pioneers such as Allergan, Inc., Sanofi S.A., Pfizer, Inc., etc. gives a positive boost to joint pain injection market growth in the North American region. Europe is second to 28 per cent due to the increasing prevalence of osteoarthritis in the geriatric population. Affordable reimbursement scenario further boosts market growth in the European region. Asia Pacific has a 20% market share due to the increasing number of trauma and accident cases and the increasing prevalence of musculoskeletal disorders.
Pharmaceutical companies pioneering in the joint pain injections market are Allergan, Plc., Anika Therapeutics, Inc., Bioventus LLC., Chugai Pharmaceutical Co., Ltd., Flexion Therapeutics, Inc., Ferring B.V., Pfizer, Inc., Sanofi S.A., SEIKAGAKU Corporation and Zimmer Biomet Holdings, Inc.
Key Market Movements:
- Rising prevalence of osteoarthritis and rheumatoid arthritis in geriatric population worldwide
- Increasing demand for hyaluronic acid injections over other surgical procedures to overcome joint pain
- Affordable reimbursement scenario associated with joint pain injections
- Hyaluronic Acid Injection
- Corticosteroid Injection
By Joint Type
- Hip Joint
- Knee & Ankle
- Shoulder & Elbow
- Facet Joints of the Spine
By Geography Segment
- North America (U.S., Rest of North America)
- Europe (U.K., Germany, France, Rest of Europe)
- Asia Pacific (China, Japan, India, Rest of Asia Pacific)
- Rest of the World (Middle East & Africa, Latin America)